## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (55% of avg), momentum weakening (-4.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($254.11)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. CHS completes $194 million sale of lab services to Labcorp By Investing.com**
- Source: Investing.com South Africa | 20251202T232600 | Somewhat-Bullish | Relevance: 99%
- Community Health Systems (NYSE:CYH) has completed the sale of select ambulatory outreach laboratory services to Labcorp (NYSE:LH) for approximately $194 million in cash. This strategic move allows CHS to focus on core services and follows other recent announcements including strong Q3 2025 earnings, surpassing revenue expectations, and plans to sell several hospitals. Truist Securities raised its price target for CHS to $4.50, maintaining a Hold rating due to the positive financial performance and strategic actions.

**2. Choreo LLC Boosts Stock Position in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251201T085514 | Neutral | Relevance: 99%
- Choreo LLC increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 83.8% in Q2, bringing their total holdings to 5,546 shares valued at $1.456 million. Despite institutional ownership reaching 95.94%, significant insider selling by Director Richelle Parham and CEO Adam Schechter has reduced insider ownership to 0.84%. Analysts currently have a consensus "Moderate Buy" rating for Labcorp, with an average target price of $297.07, and the company recently announced a quarterly dividend of $0.72 per share.

**3. Norges Bank Takes Position in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251202T113242 | Somewhat-Bullish | Relevance: 99%
- Norges Bank has initiated a new position in Labcorp Holdings Inc. (NYSE:LH), acquiring over 1 million shares valued at approximately $263.07 million, representing 1.21% of the company. This comes as Labcorp reports slightly better-than-expected quarterly EPS and strong revenue growth, alongside significant insider share sales from a director and the CEO. The company also declared a quarterly dividend and received various analyst upgrades and price target revisions.

**4. CHS completes $194 million sale of lab services to Labcorp By Investing.com**
- Source: Investing.com UK | 20251202T212600 | Bullish | Relevance: 98%
- Community Health Systems (NYSE:CYH) has completed the sale of select ambulatory outreach laboratory services to Labcorp (NYSE:LH) for approximately $194 million in cash. This strategic move allows CHS to focus on core services while expanding Labcorp's access to laboratory services across 13 states. The transaction follows recent positive financial performance for CHS, including surpassing Q3 2025 revenue expectations and a raised price target from Truist Securities.

**5. Should You Continue to Hold LH Stock in Your Portfolio?**
- Source: TradingView | 20251202T152150 | Somewhat-Bullish | Relevance: 98%
- Labcorp continues to expand its business in specialty testing areas and benefits from strategic partnerships and solid financial stability. Despite macroeconomic challenges and currency impacts, the company has shown strong earnings performance and has been active in acquisitions and share repurchases. The article suggests considering holding LH stock while also highlighting other strong healthcare stocks.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 15.2x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.8B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 15.2 |
| Current P/E | 16.3 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.0% to -0.4% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >4.0% for momentum thesis). MACD histogram positive (1.18), confirming momentum. RSI neutral at 50. Volume at 55% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.37% (CS: 56) | Neutral |
| RSI_14 | 49.9 | Neutral |
| MACD Histogram | 1.18 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 1.035x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $265.93
- **Stop Loss:** $254.11 (4.4% risk)
- **Target:** $289.57 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 84
- **Position Value:** $22,338.12
- **Portfolio %:** 22.34%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*